Financials

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
2012
AMLX
Amylyx Pharmaceuticals, Inc. - Common Stock
17.41 USD-2.03%-3.49%+17.71%+107.02%1.94 B USD
2014
URGN
UroGen Pharma Ltd. - Ordinary Shares
39.51 USD+2.46%+5.36%+33.71%+107.95%1.92 B USD
2043
GLUE
Monte Rosa Therapeutics, Inc. - Common Stock
21.98 USD-4.60%-6.43%+18.24%+94.51%1.86 B USD
2044
BCAX
Bicara Therapeutics Inc. - Common Stock
28.15 USD-2.63%-4.41%+28.36%+94.94%1.85 B USD

Frequently asked questions about Nanobiotix S.A. - ADSs

What is the Nanobiotix S.A. - ADSs stock price today?

The current price of Nanobiotix S.A. - ADSs (NBTX) is 39.15. Over the past 24 hours, the stock has changed by -2.30%. Follow the NBTX chart for real-time price dynamics.

What is the stock ticker of Nanobiotix S.A. - ADSs?

Nanobiotix S.A. - ADSs trades under the ticker NBTX. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Nanobiotix S.A. - ADSs stock going up?

NBTX has changed by -3.69% over the last week, +5.24% over the last month, and +629.05% over the last year. Review the chart to see whether the current move is part of a broader trend.

How many employees does Nanobiotix S.A. - ADSs have?

As of the latest available data, Nanobiotix S.A. - ADSs has 97 employees. Workforce size can provide additional context about the company's scale and operations.

How can I buy Nanobiotix S.A. - ADSs stock?

You can buy Nanobiotix S.A. - ADSs (NBTX) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Nanobiotix S.A. - ADSs stock?

Investing in Nanobiotix S.A. - ADSs requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the NBTX chart and related analysis on metatrader.com as part of your research.

Nanobiotix S.A. - ADSs

Nanobiotix is a biotechnology company that uses nanomedicine to develop new radiotherapy techniques for cancer patients. The company is headquartered in Paris, with additional corporate offices in New York and Massachusetts.

News